ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Silverback Therapeutics Inc (SPRY) operate in?
Silverback Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Silverback Therapeutics Inc (SPRY) current stock price?
As of the latest data, Silverback Therapeutics Inc stock price is $3.92, with a previous close of $4.03. Silverback Therapeutics Inc lost -$0.11 in the last trading session, representing a -2.73% loss.
What is Silverback Therapeutics Inc (SPRY) current market capitalization?
Silverback Therapeutics Inc market cap is approximately 389.83 million.
What is Silverback Therapeutics Inc (SPRY) Earnings Per Share (EPS)?
The trailing EPS is -$2.18, and the forward EPS is -$0.90.
What is Silverback Therapeutics Inc (SPRY) EBITDA?
Silverback Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -59.44 million.
Does Silverback Therapeutics Inc (SPRY) pay dividends?
No. Silverback Therapeutics Inc does not pay a dividend.
How did Silverback Therapeutics Inc (SPRY) perform in its most recent earnings report?
In the last report (June 30, 2026), Silverback Therapeutics Inc posted an EPS surprise of -14.55% and a revenue surprise of 7.46%.
When is Silverback Therapeutics Inc (SPRY) next earnings report?
Silverback Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Silverback Therapeutics Inc (SPRY) beta (volatility) score?
Silverback Therapeutics Inc has a beta of 0.998, meaning its volatility is roughly in line with the market.
